OBIOHealthcare · BiotechnologyThe 7 Wall Street analysts covering Orchestra Biomed Holdings, Inc. hold a median 12-month price target of $11 — +80.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 28 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Orchestra Biomed Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +80.6% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Chardan Capital | Maintains | Buy | $20 |
| 15 Sept 2026 | B. Riley Securities | Maintains | Buy | $10 → $11 |
| 15 Sept 2026 | B. Riley Securities | Maintains | Buy | — |
| 10 Sept 2026 | BTIG | Upgrade | Buy | $10 |
| 10 Sept 2026 | BTIG | Upgrade | Buy | — |
| 11 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 11 Aug 2026 | Piper Sandler | Reiterates | Overweight | $9.00 → $10 |
| 19 May 2026 | B. Riley Securities | Maintains | Buy | $12 → $10 |
| 19 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 14 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 14 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2026 | Barclays | Maintains | Overweight | $12 → $13 |
| 13 May 2026 | Barclays | Maintains | Overweight | — |
| 12 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 9 Jan 2026 | Barclays | Maintains | Overweight | — |
| 10 Dec 2025 | TD Cowen | Initiates | Buy | — |
| 13 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 12 Nov 2025 | Barclays | Maintains | Overweight | — |
| 4 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Aug 2025 | BTIG | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OBIO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Orchestra Biomed Holdings, Inc. returned +68.7% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 13% of US stocks
Cheaper than 5% of US stocks
Cheaper than 82% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 84% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Orchestra Biomed Holdings, Inc. has a market value of $360.0M and an enterprise value of $330.9M.
Revenue in the twelve months to 30 June 2026: $32.0M. The latest quarter shrank 89.5% year on year.
Net income over the same four quarters: −$59.0M, a −184.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$59.1M.
Trailing P/E: −5.4×; forward P/E: −4.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Orchestra Biomed Holdings, Inc. employs 86 people — $372K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Orchestra Biomed Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Orchestra BioMed announced that Virtue SAB will be presented at TCT 2026. The presentation will highlight its approach of infusing extended-release SirolimusEFR™ into the vessel wall to achieve sustained tissue levels.
Why it matters — The presentation puts a key feature of Orchestra BioMed’s Virtue SAB technology before a TCT 2026 audience.
Orchestra BioMed announced it will host an R&D Day on November 12, 2026, at 3:00 p.m. ET in New York City, featuring clinical insights and development plans for AVIM therapy and Virtue® SAB.
Why it matters — The event is an opportunity for OBIO watchers to hear the company’s clinical insights and development plans for these programs.
Orchestra BioMed announced it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial of AVIM Therapy, with 330 patients randomized as of September 30, 2026, exceeding the prior target of 316. The company reiterated that primary endpoint data will be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027, and the data is expected to support marketing application submissions by Medtronic to the FDA and other regulatory agencies.
Why it matters — Surpassing the enrollment target is a key trial milestone that moves the AVIM therapy forward toward potential regulatory submissions by Medtronic and a major cardiovascular conference presentation in Q2 2027.
OBIO announced that companies supported through its Capital Access Advisory Program (CAAP) have collectively raised over $1 billion in capital, marking a milestone for the program. The funding has been raised by high-growth life sciences and health tech ventures.
Why it matters — This milestone signals growing success and traction for OBIO's advisory program, which could reflect positively on the organization's standing and reach within the life sciences and health tech sectors.
Orchestra BioMed Holdings, Inc. (OBIO) saw its share price rise by 5.2% in the last trading session on above-average trading volume. The article notes that the latest trend in earnings estimate revisions for the stock suggests possible continued strength ahead.
Why it matters — A OBIO watcher would care because the rising share price, strong trading volume, and positive earnings estimate revision trend may signal growing investor confidence in the company.
The 7 Wall Street analysts covering Orchestra Biomed Holdings, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Orchestra Biomed Holdings, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Orchestra Biomed Holdings, Inc. 44 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Orchestra Biomed Holdings, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +80.6% from the last close, and Ticker Nerd's factor model ranks Orchestra Biomed Holdings, Inc. 44 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Orchestra Biomed Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $20 over the next 12 months.
Orchestra Biomed Holdings, Inc. returned +68.7% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026". Orchestra BioMed announced that Virtue SAB will be presented at TCT 2026. The presentation will highlight its approach of infusing extended-release SirolimusEFR™ into the vessel wall to achieve sustained tissue levels.
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions. Its current portfolio centers on AVIM Therapy, a bioelectronic treatment candidate designed to help lower blood pressure in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon, a drug-device platform intended for treating atherosclerotic artery disease. The company also works on cardiac neuromodulation programs and minimally invasive device technologies that support interventional procedures. Orchestra BioMed’s business model relies on partnerships with established medical device companies to advance clinical development and commercialization. Headquartered in New Hope, Pennsylvania, Orchestra BioMed plays a niche role in the medical technology market by combining device innovation, bioelectronic therapy, and targeted drug delivery within cardiovascular care.
CEO Mr. David P. Hochman · 86 employees · United States · https://www.orchestrabiomed.com
